Overview
ACE-031 is a recombinant fusion protein designed to artificially expand muscle mass by neutralizing myostatin, a natural protein that limits muscle growth. By mimicking the activin receptor type IIB, ACE-031 intercepts growth-limiting signals before they reach the muscle cells, effectively 'releasing the brakes' on muscle development. This mechanism was initially investigated as a breakthrough treatment for Duchenne Muscular Dystrophy and age-related muscle loss.
Beyond its primary focus on muscle tissue, research suggests that ACE-031 may also strengthen bone architecture and improve metabolic health. However, its development reached a significant hurdle when human clinical trials were halted due to vascular side effects. While it remains a popular subject of study in the longevity and fitness research communities for its potent anabolic effects, it is not currently approved for medical use.
Mechanism of action
It acts as a soluble 'decoy' receptor that binds to myostatin and other TGF-β ligands, preventing them from signaling through the ActRIIB receptor to inhibit muscle growth.
Reported benefits
- ▸Significant increases in lean muscle mass and volume
- ▸Enhanced muscle strength and force production
- ▸Increased bone mineral density and remodeling
- ▸Potential inhibition of muscle wasting in DMD and cancer cachexia
- ▸Improved oxidative capacity and energy metabolism in muscle tissue
- ▸Reduction in body fat storage and improved insulin sensitivity
Reported side effects
- ·Nosebleeds (epistaxis)
- ·Gum bleeding
- ·Telangiectasia (dilated blood vessels in skin)
- ·Decreased Follicle-Stimulating Hormone (FSH) in females
- ·Injection site erythema
Often stacked with
Follistatin 344BPC-157 (for tissue integrity)IGF-1 LR3